Home » Posts tagged with » Japan
Novartis’ Sandoz to acquire Aspen’s Japanese pharma business

Novartis’ Sandoz to acquire Aspen’s Japanese pharma business

Sandoz, the generic drug business of Novartis has agreed to acquire the Japanese business of Aspen Global Incorporated (AGI), a fully owned subsidiary of Aspen Pharmacare in a deal valued up to €400 million, as per the latest pharma acquisition news. The acquisition includes shares in Aspen Japan and associated assets held by the South […]

Pandion bags $795m deal with Astellas for pancreas-targeted immunomodulators

Pandion Therapeutics has bagged a $795 million worth license and collaboration deal with Japanese pharma company Astellas Pharma for the research, development, and commercialization of locally acting immunomodulators targeting autoimmune diseases of the pancreas. The collaboration will bring together the modular biologics and functional immunology expertise of Cambridge-based biotech company and Astellas Pharma’s advanced therapeutics […]

Continue reading …
Eisai, Biogen to scrap elenbecestat phase 3 studies in early AD

Eisai and Biogen have decided to stop the MISSION AD1 and AD2 phase 3 clinical studies on elenbecestat in early Alzheimer’s disease (AD) owing to safety concerns, as per the latest clinical trial news. The decision has been driven by the findings of a safety review undertaken by the Data Safety Monitoring Board (DSMB), which […]

Continue reading …
Equashield CSTD now available for oncology nurses in Japan

US medical device company Equashield through Japanese distributor Tosho has entered into an exclusive agreement with IV tube manufacturer PAL Medical to provide Equashield’s Closed System Transfer Devices (CSTDs) to oncology nurses in Japan. Post agreement, Tosho will provide PAL Medical with Equashield’s closed IV connectors to develop safer IV sets for oncology nurses administering […]

Continue reading …
Sumitomo Dainippon Pharma to buy into Roivant Sciences Vants for $3bn

Sumitomo Dainippon Pharma has signed a deal worth $3 billion to assume ownership of stakes held by Roivant Sciences in certain biopharma companies (Vants), as per the latest pharma acquisition news. The deal will help in creating a biopharma alliance between the two companies. As per the terms of the deal, the Japanese pharma company […]

Continue reading …
Maruho, X-Chem collaborate to advance drug discovery

X-Chem, a US biotech company, has entered into a drug discovery partnership with Japanese dermatology company Maruho to discover lead compounds for new and difficult targets for the treatment of human ailments. Post agreement, X-Chem will use its DNA-encoded library (DEX) screening platform to search for novel drug-like leads for Maruho targets associated with human […]

Continue reading …
Astellas doses first patient in phase 3 VMS trial of fezolinetant

Japanese pharma company Astellas Pharma has dosed the first patient in the SKYLIGHT 1 phase 3 trial for fezolinetant, an investigational oral, non-hormonal compound for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. Vasomotor symptoms are hot flashes and night sweats which occur in nearly 57% on women, aged 40-64 years as per […]

Continue reading …
Blackstone to acquire Japanese specialty pharma company AYUMI

Blackstone acquisition of AYUMI : Global investment firm Blackstone said that private equity funds managed by it will acquire Japanese specialty pharma company AYUMI Pharmaceutical from Unison Capital and M3 for an undisclosed price. AYUMI Pharmaceutical, which was founded in 2015, is focused on rheumatoid arthritis (RA) and orthopedic therapeutic areas. The Japanese specialty pharma […]

Continue reading …
Takeda acquisition of Shire : Japanese pharma company completes $62bn acquisition

Takeda acquisition of Shire : Japanese pharma company Takeda Pharmaceutical wrapped up its previously announced acquisition of Shire, an Irish biotech company with a focus on rare diseases, for $62 billion, as per the latest pharma acquisition news. Takeda acquisition of Shire It was in May 2018 when Takeda agreed to acquire the Irish rare […]

Continue reading …
Japanese pharma company Astellas acquires Potenza Therapeutics

Astellas acquisition of Potenza : Japanese pharma company Astellas Pharma has exercised an option to acquire US-based Potenza Therapeutics in a deal worth up to $404.7 million. The acquisition is a result of a collaboration agreement signed by the two pharma companies in 2015 to develop a portfolio of novel immuno-oncology (IO) therapies. In the […]

Continue reading …